CG Oncology (CGON) Equity Average (2023 - 2026)

CG Oncology (CGON) has 4 years of Equity Average data on file, last reported at $922.2 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 28.25% year-over-year to $922.2 million; the trailing twelve-month figure through Mar 2026 stood at $922.2 million (up 28.25% YoY), and the FY2025 full-year result was $743.0 million, up 143.49% from the prior year.
• Equity Average for Q1 2026 stood at $922.2 million, up from $720.1 million in the prior quarter.
• Across five years, Equity Average topped out at $922.2 million in Q1 2026 and bottomed at -$115.3 million in Q4 2023.
• The 4-year median for Equity Average is $597.9 million (2024), against an average of $448.5 million.
• The widest annual swing landed in 2024, when Equity Average soared 711.04%; it then climbed 13.39% in 2025.
• A 4-year view of Equity Average shows it stood at -$115.3 million in 2023, then surged by 650.6% to $635.1 million in 2024, then gained by 13.39% to $720.1 million in 2025, then rose by 28.06% to $922.2 million in 2026.
• The last three Equity Average figures came in at $922.2 million (Q1 2026), $720.1 million (Q4 2025), and $679.0 million (Q3 2025), per Business Quant data.

Peer Comparison